BCL2 and central nervous system cancer: For instance, CD133+ glioma CSCs express a high level of anti-apoptotic proteins Bcl-2 and Bcl-XL [45,57], and high expression of Mcl-1 correlates with resistance to the Bcl-2 inhibitor ABT-737 in glioma CSCs [57].